H.C. Wainwright lowered the firm’s price target on SAB Biotherapeutics to $6 from $10 and keeps a Buy rating on the shares post the Q4 report. The analyst cites increased operating expense assumptions and a higher fully diluted share count estimate for the target drop.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SABS:
- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
- SABS Earnings this Week: How Will it Perform?
- SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
- SAB Biotherapeutics enters partnership with Naval Medical Research Center
- SAB Biotherapeutics Secures Leadership with New Executive Contracts
